magnifying glass
logo for Genentech

Genentech

Business Services · California, United States · 13,638 Employees

Get Full Access

Who is Genentech

Genentech was founded in 1976. This company researches and manufactures pharmaceuticals for consumers with life-threatening medical conditions. Their headquarters are located in San Francisco, California.Read More

Headquarters

Headquarters:

1 Dna Way Mailstop 258A, South San Francisco, California, 94080, United States
Phone Number

Phone Number:

(650) 225-2500
Website

Website:

www.gene.com
Revenue

Revenue:

$6 Billion
Genentech's Social Media
SIC Code 28,283
NAICS Code 541711,3254
Popular Searches:

GENENTECH

Genentech Inc

Genentech , Inc.

Genentech Inc.

Genentech Access Solutions

Top Competitors of Genentech

Employess
8,574
revenue
$5 Billion

1

Employess
1,850
revenue
$2 Billion

2

Employess
23,400
revenue
$23 Billion

3

Employess
27,009
revenue
$9 Billion

4

Employess
4,000
revenue
$758 Million

5

Employess
6,000
revenue
$1 Billion

6

Genentech's Org Chart

Alexander Hardy
Alexander Hardy

Chief Executive Officer

PhonePhoneEmailEmail
Ed Harrington
Ed Harrington

Chief Financial Officer

PhonePhoneEmailEmail
Cynthia Burks
Cynthia Burks

Senior VP, Chief People & Culture O...

PhonePhoneEmailEmail

PhonePhoneEmailEmail

Genentech Email Formats

Genentech uses at least 5 email formats with last.first (ex. Smith.John@gene.com) being used 71% of the time

Get Verified Emails

Genentech Email FormatsPercentage
Illustration of an envelope

Genentech Company Metrics

Company Insights
Employee Growth Rate
Funding
Funding DateRoundAmountInvestors

Jun 30, 1976

Unspecified

$100M

Kleiner Perkins Caufield & Byers

See More

$100M

Total Funding Amount

$100M

Most Recent Funding Amount

1

Number of Funding Rounds

Revenue
QuarterRevenue

'21 - Q1

6051874000

'21 - Q2

6051874000

Acquisitions & Subsidiaries

Oct 31, 2017

PVT Probenverteiltechnik

Jun 23, 2017

Tusk Therapeutics

Dec 06, 2016

Jecure Therapeutics

Sep 16, 2013

Seragon Pharmaceuticals

Jul 24, 2013

Genable Technologies

Jan 17, 2012

Ariosa Diagnostics

See More Acquisitions & Subsidiaries

Genentech's Tech Stack

Tenable

By

Tenable

LabVIEW

By

NI

Dataiku

By

Dataiku
See more technologies

Genentech News & Media

New Pivotal Data Demonstrate Clinical Benefit of Genentech’s Glofitamab, a Potential First-in-Class Bispecific Antibody for People With Aggressive Lymphoma

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new pivotal data on its investigational CD20xCD3 T-cell engaging bispecific antibody, glofitamab, will be presented for the first time at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7 and the European Hematology Association (EHA) 2022 Congress from June 9-12. Data from the Phase II NP30179 expansion study demonstrated that,

Data at the 2022 ASCO Annual Meeting Highlight Genentech’s Continued Commitment to Innovation in Oncology and Personalized Healthcare

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 3-7, 2022. Genentech and its partners will present clinical studies across medicines, comprehensive genomic tests, and real-world data at th

Genentech Reports Interim Results for Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from its Phase III SKYSCRAPER-01 study, evaluating the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq® (atezolizumab) versus Tecentriq alone as an initial (first-line) treatment for people with PD-L1-high locally advanced or metastatic non-small cell lung cancer (NSCLC). The study did not meet its co-primary endpoint of progression-free
Subscribe to "Genentech" News

Frequently Asked Questions regarding Genentech

Where are Genentech’s headquarters?

Genentech’s headquarters are in 1 Dna Way Mailstop 258A, South San Francisco, California, 94080, United States

What is Genentech’s phone number?

Genentech’s phone number is (650) 225-2500

What is Genentech’s official website?

Genentech’s official website is www.gene.com

What is Genentech’s Revenue?

Genentech’s revenue is $6 Billion

What is Genentech’s SIC code?

Genentech’s SIC: 28,283

What is Genentech’s NAICS code?

Genentech’s NAICS: 541711,3254

How many employees are working in Genentech?

Genentech has 13,638 employees

What is Genentech’s industry?

Genentech is in the industry of: Business Services, Research & Development, Manufacturing

Who are Genentech’s main competitors?

Genentech's main competitors are: Biogen, Seattle Genetics, Amgen, CSL

What companies has Genentech acquired?

Genentech has acquired the companies: PVT Probenverteiltechnik, Tusk Therapeutics, Jecure Therapeutics, Seragon Pharmaceuticals

What is Genentech's tech stack?

The technologies that are used by Genentech are: Tenable, LabVIEW, Dataiku, Westlaw

Who is Genentech's CEO?

Genentech's CEO is Alexander Hardy

Who is Genentech's CFO?

Genentech's CFO is Ed Harrington

See more information about Genentech
4.4/5 on G2 Crowd